staree-statin-dementia-prevention

STAREE: Statins in Reducing Events in the Elderly Mind

Overview

The STAREE trial (Statins in Reducing Events in the Elderly Mind), also known as NCT05586750, is a Phase 4 clinical trial investigating whether atorvastatin can prevent dementia and cognitive decline in elderly individuals. Sponsored by Monash University in Australia, this trial represents a significant effort to identify modifiable risk factors for Alzheimer's disease and related dementias[@staree].

This landmark study addresses one of the most pressing questions in Alzheimer's disease prevention: whether statins—widely prescribed for cardiovascular disease—can also protect against cognitive decline and dementia in older adults who have no existing cognitive impairment. The trial's design addresses key limitations of previous studies that have yielded conflicting results about statin benefits for brain health.

Clinical Trial Details

STAREE: Statins in Reducing Events in the Elderly Mind

Overview

The STAREE trial (Statins in Reducing Events in the Elderly Mind), also known as NCT05586750, is a Phase 4 clinical trial investigating whether atorvastatin can prevent dementia and cognitive decline in elderly individuals. Sponsored by Monash University in Australia, this trial represents a significant effort to identify modifiable risk factors for Alzheimer's disease and related dementias[@staree].

This landmark study addresses one of the most pressing questions in Alzheimer's disease prevention: whether statins—widely prescribed for cardiovascular disease—can also protect against cognitive decline and dementia in older adults who have no existing cognitive impairment. The trial's design addresses key limitations of previous studies that have yielded conflicting results about statin benefits for brain health.

Clinical Trial Details

| Attribute | Value |
|-----------|-------|
| Trial ID | NCT05586750 |
| Official Title | Statins in Reducing Events in the Elderly Mind (STAREE) |
| Sponsor | Monash University |
| Collaborators | National Health and Medical Research Council (Australia) |
| Phase | Phase 4 |
| Status | Active, not recruiting |
| Enrollment | 341 participants |
| Actual Enrollment | 341 participants |
| Condition | Dementia, Alzheimer's Disease, Cognitive Decline |
| Intervention | Atorvastatin 40mg daily |
| Control | Placebo |
| Study Start | June 2022 |
| Estimated Completion | June 2027 |
| Primary Completion | June 2026 |

Trial Design

Study Type

• Design: Randomized, double-blind, placebo-controlled trial
• Duration: 3 years follow-up (minimum)
• Arms:
• Treatment arm: Atorvastatin 40mg daily
• Control arm: Matching placebo

Rationale for Atorvastatin 40mg

The choice of atorvastatin 40mg reflects several considerations:

Participant Flow

Inclusion Criteria

Key inclusion criteria for participant selection:

Exclusion Criteria

• Known coronary heart disease
• Previous myocardial infarction or stroke
• Established cardiovascular disease requiring lipid-lowering

• Current diagnosis of MCI or dementia
• History of neurodegenerative disease (Parkinson's, Huntington's, etc.)
• Significant traumatic brain injury

• Active liver disease or elevated LFTs
• Severe renal impairment (eGFR <30 mL/min)
• Previous adverse reaction to statins
• Myopathy or rhabdomyolysis history

• Use of contraindicated medications with atorvastatin
• Current use of strong CYP3A4 inhibitors

• Terminal illness with life expectancy <3 years
• Unable to undergo MRI
• Participation in other interventional trials

Endpoints

Primary Endpoints

• Primary cognitive measure: Change in global cognition
• Assessment: Detailed neuropsychological testing battery

• Diagnostic criteria: DSM-V or equivalent
• Adjudication: Expert panel review

• Primary MRI measure: Hippocampal volume change
• Secondary: Whole brain volume, white matter hyperintensities

Secondary Endpoints

| Category | Endpoint | Assessment |
|----------|----------|------------|
| Cardiovascular | Major adverse cardiac events (MACE) | Clinical events |
| Cognitive | Domain-specific cognitive change | Neuropsychological battery |
| Functional | Daily living activities | ADL, IADL scales |
| Behavioral | Neuropsychiatric symptoms | NPI |
| Quality of Life | Health-related QoL | SF-36, EQ-5D |
| Biomarkers | Blood-based neurodegeneration markers | Plasma Aβ, tau, NfL |
| Brain Imaging | White matter hyperintensities, connectivity | Advanced MRI |

Mechanism of Statins in Neuroprotection

Statins (HMG-CoA reductase inhibitors) exert neuroprotective effects through multiple interconnected mechanisms. Understanding these pathways helps explain why statins might prevent cognitive decline and dementia.

Cholesterol-Lowering Effects

• Lipid rafts (cholesterol-rich membrane domains) host beta- and gamma-secretases
• Reducing cholesterol decreases Abeta generation
• May also enhance Abeta clearance

• Altered neuronal signaling affects kinase/phosphatase balance
• Reduced hyperphosphorylation of tau

• Lower circulating LDL reduces atheroma formation
• Improved endothelial function in cerebral vessels
• Enhanced cerebral perfusion

Anti-Inflammatory Effects

Statins have well-documented anti-inflammatory properties that may protect against neuroinflammation:

• Microglial modulation: Reduced neuroinflammation through decreased cytokine production
• Decreased TNF-α, IL-1β, IL-6 release
• Shift from M1 (pro-inflammatory) to M2 (protective) microglial phenotype
• NF-κB inhibition: Reduced inflammatory signaling in the brain
• Statins block IKK activation
• Downstream reduction in inflammatory gene expression
• TREM2 regulation: Potential effects on microglia activity
• TREM2 variants increase AD risk
• Statins may modulate microglial TREM2 expression

Vascular Mechanisms

Given the vascular component of Alzheimer's disease (vascular contributions to cognitive impairment and dementia - VCID):

• Endothelial function: Improved nitric oxide bioavailability
• Enhanced eNOS activity
• Better vasodilatory responses
• Blood-brain barrier: Enhanced integrity
• Reduced BBB permeability
• Less perivascular inflammation
• Cerebral perfusion: Reduced small vessel disease burden
• Decreased white matter hyperintensities
• Improved cerebral blood flow autoregulation

Synaptic Protection

• Presynaptic function: Cholesterol is essential for synaptic vesicle formation
• Synaptic vesicle membranes are cholesterol-rich
• Reduced cholesterol affects neurotransmitter release
• Postsynaptic receptors: Membrane fluidity affects receptor function
• NMDA and AMPA receptor function depends on membrane environment
• Improved receptor trafficking and function
• Neurotrophic support: BDNF expression may be enhanced
• Statins may increase BDNF production
• Supports neuronal survival and plasticity

Antioxidant Effects

• Reduced oxidative stress: Decreased ROS production
• Enhanced antioxidant defenses: Increased Nrf2 pathway activity
• Mitochondrial protection: Improved mitochondrial function

Rationale for the Trial

Epidemiological Evidence

Observational studies have suggested a link between statin use and reduced dementia risk:

| Study Type | Key Finding | Reference |
|------------|------------|-----------|
| Meta-analysis | ~30% reduced risk of dementia in statin users | Song 2013[@song2013] |
| Cross-sectional | Lower prevalence of AD in statin users | Wolozin 1993[@wolozin1993] |
| Prospective cohort | Reduced cognitive decline with statins | Haag 2009[@haag2009] |
| Longitudinal | Protective effect in midlife | Li 2020[@li2020] |

• Some studies specifically implicate lipophilic statins (like atorvastatin)
• Timing of statin use (midlife vs. late-life) appears critical
• Dose-response relationships have been observed

Gaps in Evidence

Despite promising observational data, randomized controlled trials have yielded mixed results:

| Trial | Statin | Result | Limitation |
|-------|--------|--------|-----------|
| PROSPER | Pravastatin | No cognitive benefit | Late-life start, low dose |
| HPS | Simvastatin | No cognitive benefit | Mixed population |
| ASCOT-LLA | Atorvastatin | Neutral | Cardiovascular secondary prevention |

Possible explanations for negative trials:

STAREE aims to address:

Comparison with Other Statin Trials

| Trial | Design | Population | Statin/Dose | Result | Relevance to STAREE |
|-------|--------|------------|-------------|--------|-------------------|
| PROSPER | RCT, 3.5 years | Age 70-82, history of vascular disease | Pravastatin 40mg | No cognitive benefit | Similar age, but secondary prevention |
| HPS | RCT, 5 years | Age 40-80, with cardiovascular disease | Simvastatin 40mg | No cognitive benefit | Secondary prevention |
| STAREE | RCT, 3 years | Age ≥70, no dementia, statin-naïve | Atorvastatin 40mg | Ongoing | Primary prevention |
| JUPITER | RCT | Older adults with elevated CRP | Rosuvastatin 20mg | Reduced cognitive decline | Hypothesis-generating |

STAREE addresses key limitations of previous trials by:

• Recruiting primary prevention population
• Using adequate dosing
• Focusing on statin-naïve participants

Statistical Considerations

Power Analysis

• Sample size (n=341) calculated to detect 30% relative risk reduction in dementia incidence
• 80% power at α=0.05 (two-sided)
• Accounting for expected dropout (~15%)
• Assumes baseline dementia incidence of ~2% per year in this age group

Analysis Plan

• Primary analysis: Intention-to-treat
• Sensitivity analyses:
• Per-protocol analysis (adherent participants)
• As-treated analysis
• Subgroup analyses:
• Age (70-79 vs. ≥80)
• APOE4 carrier status
• Baseline cognitive function
• Baseline cardiovascular risk

Interim Analyses

• Safety monitoring at regular intervals
• No planned efficacy interim analyses to preserve statistical integrity

Current Status

As of the latest update, STAREE is:

• Status: Active, not recruiting
• Enrollment: 341 participants (fully enrolled)
• Expected completion: June 2027
• Results expected: 2028-2029

Safety Considerations

Expected Adverse Events

| Adverse Event | Frequency | Management |
|---------------|-----------|------------|
| Myalgia | 5-10% | Dose reduction, discontinuation if severe |
| Headache | 3-5% | Usually transient |
| Nausea | 2-3% | Usually transient |
| Elevated LFTs | 1-2% | Monitor, adjust dose if needed |

Serious Adverse Events (Rare)

• Rhabdomyolysis: Very rare (<0.1%), risk higher with drug interactions
• Liver injury: Rare, monitoring LFTs
• Hemorrhagic stroke: Theoretically possible, but evidence suggests no increased risk

Drug Interactions

Participants are counseled to avoid:

• Strong CYP3A4 inhibitors (clarithromycin, itraconazole, etc.)
• Grapefruit juice
• Certain immunosuppressants

Implications

If Positive

A positive result would:

If Negative

A negative result would:

Considerations for Interpretation

• Type of cognitive outcome matters: Effects on dementia incidence vs. cognitive decline may differ
• Subgroup effects: Some groups may benefit more (e.g., APOE4 carriers)
• Duration of follow-up: 3 years may be insufficient to detect effects
• Competing risks: Cardiovascular death may compete with dementia

Related Pages

• [Clinical Trials in Alzheimer's Disease](/clinical-trials/alzheimers-disease)
• [Dementia Prevention Strategies](/therapeutics/dementia-prevention)
• [Lipid Metabolism in Alzheimer's Disease](/mechanisms/lipid-metabolism-ad)
• [Cholesterol and Neurodegeneration](/mechanisms/cholesterol-neurodegeneration)
• [Cardiovascular Risk Factors for AD](/risk-factors/cardiovascular-ad)
• [Statins: Mechanism of Action](/therapeutics/statins-mechanism)
• [Atorvastatin](/drugs/atorvastatin)
• [Vascular Contributions to Cognitive Impairment](/mechanisms/vascular-cognitive-impairment)

External Links

• [ClinicalTrials.gov - STAREE (NCT05586750)](https://clinicaltrials.gov/study/NCT05586750)
• [Monash University - STAREE](https://www.monash.edu/)
• [Australian New Zealand Clinical Trials Registry](https://www.anzctr.org.au/)
• [PubMed - Statins and Dementia](https://pubmed.ncbi.nlm.nih.gov/?term=statin+dementia+Alzheimer)

References